

ForPatients

by Roche

Spinal Muscular Atrophy (SMA)

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7034067 (RG7916) Given by Mouth in Healthy Volunteers

Trial Status
Completed

Trial Runs In
1 Countries

Trial Identifier
NCT02633709 2015-004605-16
BP29840

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

The objective of this study is to assess the safety and tolerability of Risdiplam (RO7034067) in healthy people. The study will assess what the body does to Risdiplam (RO7034067) and what Risdiplam (RO7034067) does to the body. Risdiplam (RO7034067) will be given by mouth in gradually increasing doses. The data from this study will help to define the dose to further explore Risdiplam (RO7034067) in patients with Spinal Muscular Atrophy.

Hoffmann-La Roche
Sponsor

Phase 1
Phase

NCT02633709 2015-004605-16 BP29840
Trial Identifiers

Eligibility Criteria:

Gender
Male

Age
>= 18 Years & <= 45 Years

Healthy Volunteers
Accepts Healthy Volunteers
